Discover PHAGENIX
Our ambition: to become a world leader in phage therapy and address the critical medical need caused by severe resistance infections.
OUR MISSION
PHAGENIX relies on the use of phages to fight resistant bacterial infections
OUR COMBINATION
A combination that capitalizes on the expertise and complementary talents of its employees.
OUR HISTORY
PHAGENIX is a new specialty pharma focused on phage therapy.
OUR TEAM
A committed and experienced team to achieve the full potential of phage therapy.
OUR solutions
Phage therapy is now coming at the forefront of the fight against resistant bacterial infections, recognised as a major public health issue in human health.
PHAGE THERAPY
PHAGENIX develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to combat bacterial infections in humans, particularly those resistant to antibiotics.
The phages (or bacteriophages) are harmless to human organisms and specifically eradicate bacteria in an ultra-targeted way to fight microbial infections. They offer excellent efficacy against bacteria – including bacteria that are multi-resistant to antibiotics –, are very well tolerated due to their high specificity and adapt very quickly to bacterial mutations while respecting microbiota, unlike antibiotics.
SEVERE RESISTANCE INFECTIONS
Severe resistance infections are a major global public health problem, responsible today for over 1 million deaths a year worldwide, and which could, according to the World Health Organization, cause 10 million deaths a year by 2050 if nothing is done.
The growing threat of antibiotic resistance has been the main driver of the focus on developing alternative treatments, including bacteriophages.